Angiopoietin signalling is a central axis of amyloid-driven vascular dysfunction in Alzheimer’s disease
Preprint
Abstract
The neurovascular unit is critical for brain health, and its dysfunction has been linked to Alzheimer’s disease (AD). However, a cell-type-resolved understanding of how diverse vascular cells become dysfunctional and contribute to disease has been missing. Here, we applied Vessel Isolation and Nuclei Extraction for Sequencing (VINE-seq) to build a comprehensive transcriptomic atlas from 101 individuals along AD progression. Our analysis of over 842,646 parenchymal and vascular nuclei reveals that vascular dysfunction in AD is driven by transcriptional changes rather than shifts in cell proportions, with brain endothelial cells (BECs) and smooth muscle cells (SMCs) most affected. Strikingly, these molecular signatures emerge early at the mild cognitive impairment (MCI) stage, implicating vascular dysfunction early in AD pathogenesis. Stratifying by pathology reveals distinct vascular responses to β-amyloid and tau: β-amyloid burden primarily perturbs BECs and SMCs, while tau pathology predominantly impacts glial cells. We identify dysregulated angiopoietin signaling across multiple vascular cell types as a key axis, with antagonistic ANGPT2 in vascular cells and ANGPT1 in astrocytes becoming progressively dysregulated with AD. Together, this work provides a foundational resource that reveals early and pathology-specific pathways of vascular dysfunction in AD. Key Messages: VINE-seq analysis from 101 individuals creates a comprehensive human brain vascular atlas across Alzheimer’s disease (AD) progression. AD vascular dysfunction is driven by transcriptional changes rather than shifts in cell proportions, with BECs and SMCs most affected. Transcriptional signatures of vascular dysfunction emerge early at the mild cognitive impairment (MCI) stage, preceding severe cognitive symptoms and aligning more closely with AD than cognitively normal individuals. Aβ and tau associate with distinct vascular changes: Aβ mainly perturbs endothelial and smooth muscle cells, while tau impacts microglia and astrocytes. Angiopoietin signaling (antagonistic ANGPT2 in vascular cells vs. ANGPT1 in astrocytes) becomes progressively dysregulated during AD progression.Keywords
This publication has 59 references indexed in Scilit:
- Consortium to Establish a Registry for Alzheimer's Disease (CERAD): The first twenty yearsAlzheimer's & Dementia, 2008
- Mixed brain pathologies account for most dementia cases in community-dwelling older personsNeurology, 2007
- The relationship between cerebral Alzheimer's disease pathology and odour identification in old ageJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Decision Rules Guiding the Clinical Diagnosis of Alzheimer’s Disease in Two Community-Based Cohort Studies Compared to Standard Practice in a Clinic-Based Cohort StudyNeuroepidemiology, 2006
- Neuropathology of older persons without cognitive impairment from two community-based studiesNeurology, 2006
- Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctionsNeurology, 2005
- Altered Expression of Angiopoietins During Blood-Brain Barrier Breakdown and AngiogenesisLaboratory Investigation, 2003
- Identification of a novel human angiopoietin-like gene expressed mainly in heartJournal of Human Genetics, 2003
- Natural history of mild cognitive impairment in older personsNeurology, 2002
- Alzheimer Disease as a Vascular DisorderStroke, 2002